Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Eisai discovers novel selective PDE I inhibitor

March 19, 1997

Antihyperalgesic effects of bradykinin B2 antagonist from Fujisawa

March 19, 1997

JT characterizes novel COX-2 inhibitor

March 19, 1997

Novel Na+/H+-exchange inhibitor from Fujisawa with cardioprotective effects

March 19, 1997

Cardioprotective effects of KBR-9032

March 19, 1997

Gastric prokinetic agent developed by Kyorin

March 19, 1997

Potent, nonselective adenosine agonist from Schering-Plough

March 17, 1997

Water-soluble HIV protease inhibitor from Sankyo

March 14, 1997

Novo Nordisk characterizes potential antipsychotic agent

March 11, 1997

Novel LT biosynthesis inhibitor discovered by Abbott

March 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...